2024-515864-30-00
CTIS ↗
Bempedoic acid, bempedoic acid
Heterozygous familial hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
pharma · Hypercholesterolemia · Hyperlipidemia · ESPR
Esperion Therapeutics
Esperion Therapeutics trial registry — 26 ClinicalTrials.gov studies with program phase, status, and indication context.
Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ann Arbor, US
- Employees
- 5
- Programs
- 15
- Drugs
- 9
- Patents
- 55
Esperion Therapeutics clinical trials
Registry index of 26 ClinicalTrials.gov studies linked to Esperion Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Esperion Therapeutics trial registry — 26 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Esperion Therapeutics.
-
Bempedoic acid, bempedoic acid — Phase 2
Clinical update -
bempedoic acid — Phase 3
Clinical update -
Bempedoic Acid / Ezetimibe Oral Tablet — Approved
Clinical update -
Bempedoic Acid + Ezetimibe Fixed-Dose Combination — Phase 3
Clinical update -
Bempedoic acid + Ezetimibe FDC Oral Tablet — Phase 2
Clinical update -
Bempedoic acid 180mg — Phase 2
Clinical update -
Bempedoic acid 180 mg tablet — Phase 3
Clinical update -
Bempedoic Acid 180 MG Oral Tablet — Approved
Clinical update